224 related articles for article (PubMed ID: 1350744)
1. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.
Mandema JW; Kuck MT; Danhof M
Br J Pharmacol; 1992 Jan; 105(1):164-70. PubMed ID: 1350744
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity.
Mandema JW; Sansom LN; Dios-Vièitez MC; Hollander-Jansen M; Danhof M
J Pharmacol Exp Ther; 1991 Apr; 257(1):472-8. PubMed ID: 1850477
[TBL] [Abstract][Full Text] [Related]
3. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.
Mandema JW; Tukker E; Danhof M
J Pharmacol Exp Ther; 1992 Jan; 260(1):36-44. PubMed ID: 1309878
[TBL] [Abstract][Full Text] [Related]
4. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy.
Mandema JW; Kuck MT; Danhof M
J Pharmacol Exp Ther; 1992 Apr; 261(1):56-61. PubMed ID: 1560385
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol.
Tuk B; van Gool T; Danhof M
J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):235-50. PubMed ID: 12449497
[TBL] [Abstract][Full Text] [Related]
6. Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs.
Danhof M; Mandema JW
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):516-9. PubMed ID: 1490817
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.
Mandema JW; Tukker E; Danhof M
Br J Pharmacol; 1991 Mar; 102(3):663-8. PubMed ID: 1364836
[TBL] [Abstract][Full Text] [Related]
8. Apparent pA2 values of benzodiazepine antagonists and partial agonists in monkeys.
Paronis CA; Bergman J
J Pharmacol Exp Ther; 1999 Sep; 290(3):1222-9. PubMed ID: 10454498
[TBL] [Abstract][Full Text] [Related]
9. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.
Mandema JW; Danhof M
Clin Pharmacokinet; 1992 Sep; 23(3):191-215. PubMed ID: 1511536
[TBL] [Abstract][Full Text] [Related]
10. Semilinear canonical correlation applied to the measurement of the electroencephalographic effects of midazolam and flumazenil reversal.
Schnider TW; Minto CF; Fiset P; Gregg KM; Shafer SL
Anesthesiology; 1996 Mar; 84(3):510-9. PubMed ID: 8659777
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.
Mandema JW; Danhof M
J Pharmacokinet Biopharm; 1990 Oct; 18(5):459-81. PubMed ID: 1979991
[TBL] [Abstract][Full Text] [Related]
12. Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones.
Yakushiji T; Fukuda T; Oyama Y; Akaike N
Br J Pharmacol; 1989 Nov; 98(3):735-40. PubMed ID: 2574062
[TBL] [Abstract][Full Text] [Related]
13. Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo.
Malizia AL; Gunn RN; Wilson SJ; Waters SH; Bloomfield PM; Cunningham VJ; Nutt DJ
Neuropharmacology; 1996; 35(9-10):1483-91. PubMed ID: 9014164
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats.
Cox EH; Van Hemert JG; Tukker EJ; Danhof M
J Pharmacol Toxicol Methods; 1997 Oct; 38(2):99-108. PubMed ID: 9403781
[TBL] [Abstract][Full Text] [Related]
15. Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic-pharmacodynamic relationships in individual animals.
Laurijssens BE; Greenblatt DJ
J Pharm Pharmacol; 2002 Jan; 54(1):77-86. PubMed ID: 11829133
[TBL] [Abstract][Full Text] [Related]
16. [The action of the benzodiazepine antagonist Ro 15-1788].
Doenicke A; Suttmann H; Kapp W; Kugler J; Ebentheuer H
Anaesthesist; 1984 Aug; 33(8):343-7. PubMed ID: 6148904
[TBL] [Abstract][Full Text] [Related]
17. EEG-β/γ spectral power elevation in rat: a translatable biomarker elicited by GABA(Aα2/3)-positive allosteric modulators at nonsedating anxiolytic doses.
Christian EP; Snyder DH; Song W; Gurley DA; Smolka J; Maier DL; Ding M; Gharahdaghi F; Liu XF; Chopra M; Ribadeneira M; Chapdelaine MJ; Dudley A; Arriza JL; Maciag C; Quirk MC; Doherty JJ
J Neurophysiol; 2015 Jan; 113(1):116-31. PubMed ID: 25253471
[TBL] [Abstract][Full Text] [Related]
18. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.
Dingemanse J; van Gerven JM; Schoemaker RC; Roncari G; Oberyé JJ; van Oostenbruggen MF; Massarella J; Segala P; Zell M; Cohen AF
Br J Clin Pharmacol; 1997 Nov; 44(5):477-86. PubMed ID: 9384465
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of Ro 48-6791, a new short-acting benzodiazepine, in young and elderly subjects.
Dingemanse J; Häussler J; Hering W; Ihmsen H; Albrecht S; Zell M; Schwilden H; Schüttler J
Br J Anaesth; 1997 Nov; 79(5):567-74. PubMed ID: 9422892
[TBL] [Abstract][Full Text] [Related]
20. Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy.
Cleton A; Voskuyl RA; Danhof M
Br J Pharmacol; 1998 Oct; 125(4):615-20. PubMed ID: 9831893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
